The Food and Drug Administration’s (FDA) recently convened expert panel on talc may not generate headlines like a new vaccine or breakthrough cancer drug, but it deserves the full attention of every American who cares about science, transparency, and personal freedom. Despite what critics might claim about supposed “cuts” to scientific research under the Trump administration, what we are seeing now with the FDA’s talc inquiry is how government should approach health policy: identify a potential concern, gather credible experts, and evaluate the evidence deliberately before acting.
Let’s state the obvious: The use of talc—whether in cosmetics, food, or pharmaceuticals—is widespread. Talc is in a number of foodstuffs and health care products. An estimated 20 million Americans ingest it every day. And while talc itself has long been considered safe for ingestion, increasing evidence has raised uncomfortable but essential questions: Is talc itself a carcinogen, or is the problem limited to asbestos contamination in some talc sources? Can talc trigger inflammatory diseases or contribute to rising rates of gastrointestinal cancers in young Americans? Are there lower-risk alternatives? These are not conspiracy theories. These are questions rooted in science and worthy of investigation.
That’s what the FDA has done. Instead of issuing sweeping bans or bureaucratic overreach, the agency assembled a panel of experts—including pathologists, toxicologists, epidemiologists, industry chemists, and regulatory veterans from around the globe—to examine the facts. This is government at its best: humble enough to admit what we don’t yet know and confident enough to ask the hard questions in a public forum. Contrast this with past health panics—like the poorly handled asbestos saga—that were driven more by fear and litigation than by evidence or deliberation.
- Talc has been noted for possible inflammation and carcinogenic activity in animal studies going back to a 1993 National Toxicology Program report. More recently, a 2019 meta-analysis of 30 human studies found an odds ratio of 1.3 between perineal talc use and ovarian cancer—a statistically significant increase that cannot be ignored.
- Talc is a known pro-inflammatory substance. Surgeons, including Dr. Marty Makary (who led the FDA’s roundtable), have used talc in pleurodesis procedures because it causes a powerful inflammatory reaction. This property, while medically useful in one context, raises serious concerns when the same substance is consumed or inhaled regularly without medical oversight.
- There are viable, low-cost alternatives to talc in food and pharmaceuticals—such as magnesium stearate—that perform the same function without the same risk profile.
That’s the beauty of this inquiry: It dares to ask not just whether talc causes cancer but whether we have overlooked a major dietary and pharmaceutical exposure that may be contributing to America’s chronic disease burden. As Dr. Makary pointed out in the FDA’s podcast, 40 percent of American children now live with a chronic condition, and the rates of GI cancer in young people are rising with no clear explanation. No one is claiming talc is the sole cause—but shouldn’t we want to rule it out?
This is where the conservative philosophy of limited but effective government shines. We don’t need knee-jerk bans. We need data, deliberation, and direction. We need to recognize risk in context—not exaggerate it but not minimize it either. And we need to respect the public by communicating clearly, honestly, and without fearmongering.
That’s also why this talc inquiry is a rebuke to the critics who love to repeat the tired talking point that conservatives “don’t believe in science.” On the contrary—we believe that science should be rigorous, methodical, and independent of ideological or financial influence. We oppose politicized science, not science itself. And the FDA panel, made up of professionals from the National Institutes of Health, Stanford, Emory, Brigham & Women’s, Monash University in Australia, and leading pharmaceutical firms, proves that you can trust science when it’s done transparently and with intellectual humility.
That’s why this panel’s approach is so important: It focuses not just on the presence of risk but the balance of risk and benefit. Do we need talc to keep gum from sticking to its wrapper? Do we need it in baby powder, when safer alternatives exist? Can we reformulate legacy medications to use a substitute? Can we avoid the chaos of the asbestos debates by getting ahead of the science, instead of denying or litigating it into oblivion?
The answers are still unfolding. But the process is working. That’s the lesson here.
Let’s hope the FDA stays the course—and that Congress supports its efforts to ask tough questions without political pressure. Let’s also hope that industry pays attention. Reformulating products isn’t always cheap or easy, but the panelists made clear: It is doable. Several generic medications already use talc-free formulations. Alternatives like magnesium stearate are cost-effective and widely available. There’s no reason we should cling to an outdated compound if there’s a safer path forward.
That’s the kind of science-driven policy conservatives should champion—not because it expands government but because it improves government. This isn’t about banning candy or pills. It’s about making sure the ingredients in them aren’t slowly harming us when better options exist.